Clinical characteristics and prognostic factors of patients with gastric neuroendocrine carcinoma treated with radical surgery.
- Author:
Xuefeng XU
1
;
Jian'ang LI
1
;
Xu HAN
1
;
Chenye SHI
1
;
Dayong JIN
1
;
Wenhui LOU
2
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Aged, 80 and over; Carcinoma, Neuroendocrine; surgery; Female; Humans; Male; Middle Aged; Prognosis; Stomach Neoplasms; surgery; Survival Analysis
- From: Chinese Medical Journal 2014;127(13):2419-2422
- CountryChina
- Language:English
-
Abstract:
BACKGROUNDGastric neuroendocrine carcinomas (g-NECs) are rare tumors that have aggressive biological behaviors and poor prognosis, but the prognostic factors of postoperative patients with g-NEC are still unclear. Our aim was to study and explore the clinical characteristics and prognostic factors of patients with g-NEC treated with radical surgery.
METHODSThe clinical data of 43 g-NEC patients who underwent surgery from January 2002 to January 2011 at the Zhongshan Hospital of Fudan University were analyzed. Follow-up was conducted by telephone, mail, or returning visit survey.
RESULTSThe sizes of the 43 neuroendocrine carcinomas (G3) were 1.5 cm × 1.5 cm × 0.5 cm to 7 cm × 8 cm × 1.5 cm. Eight NECs were localized, and 35 had lymph node involvement, of which 1 also had hepatic metastasis. At the end of the follow-up, the follow-up rate was 97.7% (42/43), and the median follow-up time was 22.2 months. The median overall survival of g-NEC patients was 36.5 months, and the 1-, 3-, and 5-year overall survival rates were 86.0%, 51.6%, and 36.7%, respectively. Sex (P < 0.05) and lymph node involvement (P < 0.05) were prognostic factors of postoperative g-NEC patients, among which sex was an independent prognostic factor (P < 0.05), as a survival advantage of female patients over male was observed.
CONCLUSIONSMost of the g-NECs were diagnosed at an advanced stage. The prognosis of g-NECs was related with sex and lymph node involvement, of which sex was an independent prognostic factor, with female patients having a survival advantage.